According to the latest data from the Hong Kong Stock Exchange, on October 6, Chairman and CEO Liang Wenqing increased his holdings in CF PharmTech (02652) by 19,300 shares at a price of HK$6.9216 per share, for a total amount of approximately HK$133,600.
Following the increase, his latest shareholding stands at approximately 60,716,500 shares, representing an 18.74% stake in the company.
Supplementary information: Pursuant to the Acting-in-Concert Agreement, Dr. LIANG Bill Wenqing and Dr. LI LI BOVET are parties acting in concert. As such, under the SFO, each of Dr. LIANG and Dr. LI LI BOVET is deemed to be interested in the shares the other is interested in.
Comments